RESTRUCTURING AND IMPAIRMENT (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 305	[1]
Lease settlement	101	[2]
Total restructuring	406
Impairment of royalties buyout	576	[3]
Total restructuring and impairment	$ 982

[1] During the year ended December 31, 2015, the company incurred $305,000 of costs associated with reducing the Company's headcount.

[2] On November 5, 2015, the Company entered into a second amendment (the "Second Lease Amendment") to the lease agreement for its facilities in the U.S. Pursuant to the Second Lease Amendment and effective January 1, 2016, the Company agreed to reduce its leased space and surrender the released premises. The Company also agreed to pay transaction costs and settlement amount of $101,000.

[3] During the year ended December 31, 2015 the Company recorded expenses related to the impairment of the royalties buyout asset amounting to $576,000 due to anticipated lower sales of MGuard Prime in the future resulting from industry preferences for drug eluting stents.